S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PALI · Palisade Bio, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$1.39
-0.04
(-2.80%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.39
$1.39
$1.45
52-WEEK RANGE
$1.39
$1.32
$2.85
What's happening
- PALI is down 2.80% today, trading at $1.39. — Live quote
- Volume today (121,443) is well below its 3-month average of 3,037,830. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.05 actual vs. $-0.05 estimated (+6.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PALI
-39.15%
vs S&P 500
-51.93%
1-YEAR RETURN
PALI
-23.12%
vs S&P 500
-37.68%
6-MONTH RETURN
PALI
-38.63%
3-MONTH RETURN
PALI
-25.52%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.05
Est. $-0.05
BEAT +6.2%
2026-04-26 (Q1 2026)
$-0.05
Est. $-0.04
MISS -14.4%
2026-01-26 (Q4 2025)
$-0.08
Est. $-0.08
BEAT +3.5%
2025-10-26 (Q3 2025)
$-0.38
Est. $-0.28
MISS -35.8%
Valuation Measures & Ratios
Enterprise Value4$122.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)495.80
Price / Book72.98
EV4 / Revenue245.46
EV4 / EBITDA—
Profit Margin-2114.80%
Operating Margin-2339.60%
Return on Equity (ROE8)-33.47%
Return on Assets (ROA9)-31.79%
Avg Volume (3M)3,037,830
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $444.1M | $336.0M | $6.4M | $3.3M | $3.1M |
| P/E | -17.20 | -19.22 | -0.56 | -0.26 | -0.23 |
| Price/Book | 3.65 | 2.64 | 1.98 | 1.24 | 0.58 |
| ROE | -21.21% | -13.73% | -353.95% | -480.19% | -249.93% |
| ROA | -20.29% | -13.11% | -163.04% | -188.71% | -162.69% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short31,015,282
Change from Prior Settlement+2.47%
% of Float—
Days to Cover (Short Ratio)6.06
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-21; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -2114.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -23.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PALI
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | — | — | $0 | — | $0 | $0 | $0 |
| Operating income | -$11.7M | -$10.7M | -$2.9M | -$2.8M | -$2.3M | -$3.6M | -$4.2M | -$3.7M |
| Net income | -$10.6M | -$9.6M | -$2.9M | -$2.8M | -$2.2M | -$3.5M | -$4.1M | -$3.5M |
| EPS (diluted) | $-0.05 | $-0.05 | $-0.38 | $-0.58 | $-0.47 | $-2.32 | $-3.32 | $-4.59 |
| EPS (basic) | $-0.05 | $-0.05 | $-0.38 | $-0.58 | $-0.47 | $-2.32 | $-3.32 | $-4.59 |
| Operating margin | -$2.3K | — | — | — | — | — | — | — |
| Net margin | -$2.1K | — | — | — | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $127.3M | $133.3M | $134.3M | $7.0M | $6.7M | $8.2M | $10.9M | $9.3M |
| Total liabilities | $5.6M | $6.0M | $5.0M | $3.8M | $4.0M | $2.9M | $3.4M | $2.7M |
| Stockholders' equity | $121.7M | $127.4M | $129.4M | $3.2M | $2.6M | $5.3M | $7.5M | $6.6M |
| Total current assets | $127.3M | $133.2M | $134.2M | $6.8M | $6.4M | $7.9M | $10.5M | $8.9M |
| Total current liabilities | $5.2M | $5.6M | $4.6M | $3.5M | $4.0M | $2.8M | $3.2M | $2.7M |
| Cash & equivalents | $125.2M | $132.6M | $133.4M | $5.2M | $5.4M | $7.2M | $9.8M | $8.0M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $500.0K | — | $0 | — | $0 | — | $0 | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | $0 | $0 | $1.0K | $2.0K | $3.0K | $3.0K |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $0 | $17.0K | $68.0K | $119.0K | $171.0K | $222.0K | $273.0K | $324.0K |
| Accounts payable | $1.8M | $2.7M | $767.0K | $1.4M | $1.4M | $745.0K | $1.1M | $366.0K |
| Accrued liabilities | $3.1M | $2.8M | $2.2M | $1.2M | $2.1M | $1.9M | $1.2M | $1.5M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | $283.0K | — | — | $150.0K | — |
| Common stock & paid-in capital | $1.7M | $1.7M | $1.6M | $91.0K | $48.0K | $43.0K | $27.0K | $11.0K |
| Retained earnings | — | — | — | — | $141.0M | $138.2M | $135.9M | $132.6M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.6M | -$3.9M | -$3.1M | -$3.6M | -$1.8M | -$2.3M | -$2.4M | -$3.1M |
| Investing cash flow | — | — | — | — | — | — | $0 | $0 |
| Financing cash flow | $147.0K | $3.1M | $131.3M | $3.4M | $4.0K | -$258.0K | $4.2M | -$180.0K |
| Free cash flow | — | — | — | — | — | — | -$2.4M | -$3.1M |
| Capital expenditures | — | — | — | — | — | — | $0 | $0 |
| Share-based compensation | $4.8M | $4.3M | $3.7M | $90.0K | $69.0K | $69.0K | $77.0K | $95.0K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $500.0K | — | — | — | $0 | — | — | — |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | $0 | $0 | $0 | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $250.0K | $0 | — |
| Operating income | -$18.1M | -$14.9M | -$13.1M | -$15.7M | -$41.9M |
| Net income | -$16.8M | -$14.4M | -$12.3M | -$14.3M | -$26.6M |
| EPS (diluted) | $-0.30 | $-10.19 | $-27.01 | $-16.53 | $-169.74 |
| EPS (basic) | $-0.30 | $-10.19 | $-27.01 | $-16.53 | $-142.95 |
| Operating margin | — | — | -$5.2K | — | — |
| Net margin | — | — | -$4.9K | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $134.3M | $10.9M | $14.1M | $15.8M | $12.5M |
| Total liabilities | $5.0M | $3.4M | $2.7M | $3.3M | $5.1M |
| Stockholders' equity | $129.4M | $7.5M | $11.3M | $12.5M | $7.4M |
| Total current assets | $134.2M | $10.5M | $13.3M | $14.7M | $11.5M |
| Total current liabilities | $4.6M | $3.2M | $2.6M | $3.0M | $2.5M |
| Cash & equivalents | $133.4M | $9.8M | $12.4M | $12.4M | $10.5M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | — | — | — | — | $0 |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $0 | $3.0K | $10.0K | $10.0K | $3.0K |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | $68.0K | $273.0K | $490.0K | $694.0K | $868.0K |
| Accounts payable | $767.0K | $1.1M | $698.0K | $1.8M | $1.3M |
| Accrued liabilities | $2.2M | $1.2M | $831.0K | $574.0K | $463.0K |
| Short-term debt | — | — | — | — | $87.0K |
| Other current liabilities | — | — | — | — | — |
| Long-term debt | — | — | — | — | $0 |
| Common stock & paid-in capital | $1.6M | $27.0K | $6.0K | $30.0K | $3.0K |
| Retained earnings | — | $135.9M | $121.5M | $109.2M | $94.6M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.8M | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
| Investing cash flow | — | $0 | -$4.0K | -$10.0K | -$54.0K |
| Financing cash flow | $134.4M | $9.6M | $11.2M | $15.3M | $24.6M |
| Free cash flow | — | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
| Capital expenditures | — | $0 | $4.0K | $10.0K | $0 |
| Share-based compensation | $4.0M | $652.0K | $624.0K | $1.0M | $1.9M |
| Deferred income taxes | — | — | — | — | $0 |
| Change in accounts receivable | — | — | — | $0 | -$84.0K |
| Purchases of investments | — | — | — | — | — |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $25.0K | $0 | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PALI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-09 to 2026-10-19
Recent transactions
- Insiders have net sold 53,678 shares over the last 182 days, across 8 purchases and 2 sales.
- Most recent: Capers Julien E. (See Remarks) — Grant / award of 787,300 shares on 2026-10-19.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)145,000 sh(8 txns)
Sales (open market)198,678 sh(2 txns)
Net Shares-53,678
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Capers Julien E. | See Remarks | Grant / award | 2026-10-19 | 787,300 |
| Jones Mitchell Lawrence | See Remarks | Option exercise | 2026-10-06 | 2,620,850 |
| Finley John David | CEO CFO | Option exercise | 2026-10-06 | 3,227,384 |
| Williams Donald Allen | Director | Open market purchase | 2026-10-02 | 10,000 |
| Baltera Robert Jr. | Director | Open market purchase | 2026-07-09 | 25,000 |
| Wei Binxian | Director | Grant / award | 2026-06-10 | 592,300 |
| Chuang Emil | Director | Grant / award | 2026-06-10 | 592,300 |
| Zwick Jordan Michael | Director | Grant / award | 2026-06-10 | 336,904 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-19 | Capers Julien E. | See Remarks | Grant / award | 787,300 | — |
| 2026-10-06 | Jones Mitchell Lawrence | See Remarks | Option exercise | 2,620,850 | — |
| 2026-10-06 | Jones Mitchell Lawrence | See Remarks | Tax withholding | 1,031,102 | $1.49 |
| 2026-10-06 | Finley John David | CEO CFO | Option exercise | 3,227,384 | — |
| 2026-10-06 | Finley John David | CEO CFO | Tax withholding | 1,411,982 | $1.49 |
| 2026-10-02 | Williams Donald Allen | Director | Open market purchase | 10,000 | $1.46 |
| 2026-10-01 | Williams Donald Allen | Director | Open market purchase | 10,000 | $1.42 |
| 2026-08-19 | Finley John David | CEO, CFO | Gift | 88,400 | $0.00 |
| 2026-08-19 | Finley John David | CEO, CFO | Gift | 88,400 | $0.00 |
| 2026-07-09 | Baltera Robert Jr. | Director | Open market purchase | 25,000 | $1.96 |
| 2026-07-08 | Baltera Robert Jr. | Director | Open market purchase | 20,000 | $1.99 |
| 2026-07-07 | Baltera Robert Jr. | Director | Open market purchase | 30,000 | $2.03 |
| 2026-07-07 | Jones Mitchell Lawrence | Chief Medical Officer | Open market sale | 51,880 | $2.05 |
| 2026-07-07 | Finley John David | CEO, CFO | Open market sale | 146,798 | $2.07 |
| 2026-07-07 | Finley John David | CEO, CFO | Option exercise | 133 | $0.70 |
| 2026-07-06 | Baltera Robert Jr. | Director | Open market purchase | 20,000 | $2.05 |
| 2026-07-06 | Jones Mitchell Lawrence | Chief Medical Officer | Option exercise | 131,167 | — |
| 2026-07-06 | Finley John David | CEO, CFO | Option exercise | 335,167 | — |
| 2026-07-02 | Baltera Robert Jr. | Director | Open market purchase | 10,000 | $1.98 |
| 2026-07-01 | Baltera Robert Jr. | Director | Open market purchase | 20,000 | $1.98 |
| 2026-06-10 | Baltera Robert Jr. | Director | Grant / award | 336,904 | — |
| 2026-06-10 | Wei Binxian | Director | Grant / award | 592,300 | — |
| 2026-06-10 | Wei Binxian | Director | Option exercise | 20,200 | — |
| 2026-06-10 | Williams Donald Allen | Director | Grant / award | 1,498,900 | — |
| 2026-06-10 | Williams Donald Allen | Director | Option exercise | 60,666 | — |
| 2026-06-10 | Chuang Emil | Director | Grant / award | 592,300 | — |
| 2026-06-10 | Chuang Emil | Director | Option exercise | 20,200 | — |
| 2026-06-10 | Zwick Jordan Michael | Director | Grant / award | 336,904 | — |
| 2026-02-12 | Jones Mitchell Lawrence | Chief Medical Officer | Open market sale | 1,989 | $1.75 |
| 2026-02-12 | Finley John David | CEO, CFO | Open market sale | 3,896 | $1.75 |
| 2026-02-11 | Jones Mitchell Lawrence | Chief Medical Officer | Option exercise | 8,000 | — |
| 2026-02-11 | Finley John David | CEO, CFO | Option exercise | 13,333 | — |
| 2026-01-16 | Williams Donald Allen | Director | Open market purchase | 5,000 | $1.67 |
| 2026-01-09 | Williams Donald Allen | Director | Open market purchase | 5,000 | $1.88 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:20 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-21 | 4 | 2026-10-19 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-10 | 4 | 2026-07-08 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
Recent news
Headlines about PALI (Palisade Bio, Inc.). Links open the publisher — we don’t host full articles.
-
Form 4 Palisade Bio Inc: Julien E. Capers (Officer) For: 19 October
Investing.com Australia · 2026-10-21 -
Silver Rate Today in Pali 22nd October 2026 : 1 KG, Todays Silver Price in Pali
Business Today · 2026-10-21 -
Counsel receives 787,300 stock units at Palisade Bio (PALI), subject to service-based vesting.
Stock Titan · 2026-10-21 -
Oppenheimer reiterates Palisade Bio stock rating on Crohn’s data
Investing.com · 2026-10-21 -
Palisades Goldcorp Ltd. (TSXV:PALI) Gains Bullish Momentum as Investor Interest Strengthens
kalkine.ca · 2026-10-21 -
Gold Rate Today in Pali 21st October 2026 : 22 & 24 Carat, Todays Gold Price in Pali
Business Today · 2026-10-21 -
Palisade Bio, Inc. (PALI) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Palisade Bio reports early-stage Crohn’s disease trial results By Investing.com
Investing.com Nigeria · 2026-10-20
No headlines in this category right now — try “All”.